Condition (MeSH)
Cardiomyopathy, Restrictive
ClinicalTrials.gov lists 15 trials for Cardiomyopathy, Restrictive or a narrower condition beneath it. Tenaya Therapeutics has the most among industry and government lead sponsors, with 1.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
15 of the 15 trials are tagged with Cardiomyopathy, Restrictive itself; the rest are tagged with a narrower condition beneath it.
When did Cardiomyopathy, Restrictive trials start? (10)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Not applicable
- Observational
Top of scale: 3
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2025 | 2 |
| 2024 | 1 |
| 2023 | 1 |
| 2021 | 2 |
| 2018 | 3 |
| 2016 | 1 |
| 2015 | 1 |
| 2014 | 1 |
| 2013 | 2 |
| 2007 | 1 |
No forecast is made for this condition: it averages 1.0 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: none of the 15 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Cardiomyopathy, Restrictive trials in? (2)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Not applicable | 2 |
| Observational | 13 |
How many Cardiomyopathy, Restrictive trials are recruiting? (7)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 2 |
| Recruiting | 5 |
| Enrolling by invitation | 1 |
| Active, not recruiting | 1 |
| Completed | 2 |
Showing 5 of 7 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Cardiomyopathy, Restrictive trials? (1)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Tenaya Therapeutics | 1 |
Interventions as named in the registry (3)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Routine Treatment | 1 |
| diuretics, ACEIs/ARBs, beta blockers, positive inotropic drugs, MRAs, SGLT2i, retinoids | 1 |
| MRI | 1 |
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which publications cover Cardiomyopathy, Restrictive? (13)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Treatment Strategies for Cardiomyopathy in Children: A Scientific Statement From the American Heart Association. | Circulation | 2023 | Yes |
| Heart failure in cardiomyopathies: a position paper from the Heart Failure Association of the European Society of Cardiology. | European journal of heart failure | 2019 | Yes |
| Hip and knee arthroplasty are common among patients with transthyretin cardiac amyloidosis, occurring years before cardiac amyloid diagnosis: can we identify affected patients earlier? | Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis | 2017 | Yes |
| The amyloidogenic V122I transthyretin variant in elderly black Americans. | The New England journal of medicine | 2015 | Yes |
| Outcomes of restrictive cardiomyopathy in childhood and the influence of phenotype: a report from the Pediatric Cardiomyopathy Registry. | Circulation | 2012 | Yes |
Showing 5 of 13 publications.
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Restrictive cardiomyopathy | 217632 | Exact | Orphanet Rare Disease Ontology (ORDO) |
| Restrictive cardiomyopathy | 217632 | Exact | Orphadata Science knowledge files, Product 1 |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: serious adverse events in this condition's trials, prevalence, and sub-conditions in mesh.